Nifty

:

22643.40

Sensex

:

74671.28

223.45 (1.00%)
941.12 (1.28%)

Login

Nifty
Sensex

:
:

22643.40
74671.28

223.45 (1.00%)
941.12 (1.28%)

Valiant Laboratories Ltd.

Pharmaceuticals & Drugs

Rating :

48/99

BSE: 543998 | NSE: VALIANTLAB

Watchlist

NSE BSE

159.00

29-Apr-2024

Open
High
Low
Previous Close

157.30
160.10
155.10
157.30

Volume
Traded Value (lacs)
52 Week High
52 Week Low

34608
54.66
214.95
139.00

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

682.38
23.53
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

740.09
N/A
2.68

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
-
-

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-
-

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-
-

P:E (Median)

8 Years
5 Years
3 Years

-
-
-

P:BV (Average)

8 Years
5 Years
3 Years

-
-
-

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
-

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 40.52 70.77 -42.74% 59.55 87.96 -32.30% 0.00 0.00 0 0.00 0.00 0
Expenses 46.82 60.85 -23.06% 60.93 77.27 -21.15% 0.00 0.00 0 0.00 0.00 0
EBITDA -6.31 9.93 - -1.39 10.68 - 0.00 0.00 0 0.00 0.00 0
EBIDTM -15.57% 14.03% -2.33% 12.15% 0.00% 0.00% 0.00% 0.00%
Other Income 1.77 0.78 126.92% 2.96 1.47 101.36% 0.00 0.00 0 0.00 0.00 0
Interest 0.02 0.04 -50.00% 0.02 0.17 -88.24% 0.00 0.00 0 0.00 0.00 0
Depreciation 0.49 0.40 22.50% 0.49 0.37 32.43% 0.00 0.00 0 0.00 0.00 0
PBT -5.04 10.27 - 1.06 11.61 -90.87% 0.00 0.00 0 0.00 0.00 0
Tax -1.54 2.62 - 0.27 2.96 -90.88% 0.00 0.00 0 0.00 0.00 0
PAT -3.50 7.65 - 0.79 8.66 -90.88% 0.00 0.00 0 0.00 0.00 0
PATM -8.65% 10.80% 1.33% 9.84% 0.00% 0.00% 0.00% 0.00%
EPS -0.81 1.76 - 0.18 2.00 -91.00% 0.00 0.00 0 0.00 0.00 0

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 40.52 70.77 -42.74% 59.55 87.96 -32.30% 0.00 0.00 0 0.00 0.00 0
Expenses 46.82 60.85 -23.06% 60.93 77.27 -21.15% 0.00 0.00 0 0.00 0.00 0
EBITDA -6.31 9.93 - -1.39 10.68 - 0.00 0.00 0 0.00 0.00 0
EBIDTM -15.57% 14.03% -4.88% -4.88% 0.00% 0.00% 0.00% 0.00%
Other Income 1.77 0.78 126.92% 2.96 1.47 101.36% 0.00 0.00 0 0.00 0.00 0
Interest 0.02 0.04 -50.00% 0.02 0.17 -88.24% 0.00 0.00 0 0.00 0.00 0
Depreciation 0.49 0.40 22.50% 0.49 0.37 32.43% 0.00 0.00 0 0.00 0.00 0
PBT -5.04 10.27 - 1.06 11.61 -90.87% 0.00 0.00 0 0.00 0.00 0
Tax -1.54 2.62 - 0.27 2.96 -90.88% 0.00 0.00 0 0.00 0.00 0
PAT -3.50 7.65 - 0.79 8.66 -90.88% 0.00 0.00 0 0.00 0.00 0
PATM -8.65% 10.80% -10.84% -10.84% 0.00% 0.00% 0.00% 0.00%
EPS -0.81 2.35 - -0.96 -0.96 - 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description TTM Mar 23 Mar 22
Net Sales - 333.91 291.52 Net Sales Growth - 14.54% Cost Of Goods Sold - 276.52 234.22 Gross Profit - 57.39 57.30 GP Margin - 17.19% 19.66% Total Expenditure - 298.82 249.21 Power & Fuel Cost - 7.37 4.38 % Of Sales - 2.21% 1.50% Employee Cost - 4.61 3.06 % Of Sales - 1.38% 1.05% Manufacturing Exp. - 5.22 3.93 % Of Sales - 1.56% 1.35% General & Admin Exp. - 0.74 0.53 % Of Sales - 0.22% 0.18% Selling & Distn. Exp. - 2.94 2.03 % Of Sales - 0.88% 0.70% Miscellaneous Exp. - 1.43 1.06 % Of Sales - 0.43% 0.36% EBITDA - 35.09 42.31 EBITDA Margin - 10.51% 14.51% Other Income - 4.86 1.95 Interest - 0.25 0.07 Depreciation - 1.56 2.49 PBT - 38.14 41.70 Tax - 9.14 14.21 Tax Rate - 23.96% 34.08% PAT - 29.00 27.50 PAT before Minority Interest - 29.00 27.50 Minority Interest - 0.00 0.00 PAT Margin - 8.68% 9.43% PAT Growth - 5.45% EPS - 6.68 6.34

Description TTM Mar 23
Net Sales - 333.91 Net Sales Growth - Cost Of Goods Sold - 276.52 Gross Profit - 57.39 GP Margin - 17.19% Total Expenditure - 298.82 Power & Fuel Cost - 7.37 % Of Sales - 2.21% Employee Cost - 4.61 % Of Sales - 1.38% Manufacturing Exp. - 5.22 % Of Sales - 1.56% General & Admin Exp. - 0.74 % Of Sales - 0.22% Selling & Distn. Exp. - 2.94 % Of Sales - 0.88% Miscellaneous Exp. - 1.43 % Of Sales - 0.43% EBITDA - 35.09 EBITDA Margin - 10.51% Other Income - 4.86 Interest - 0.25 Depreciation - 1.56 PBT - 38.14 Tax - 9.14 Tax Rate - 23.96% PAT - 29.00 PAT before Minority Interest - 29.00 Minority Interest - 0.00 PAT Margin - 8.68% PAT Growth - EPS - 6.68

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 23 Mar 22
Shareholder's Funds 100.49 71.46 Share Capital 32.56 16.28 Total Reserves 67.93 55.18 Non-Current Liabilities 61.75 60.92 Secured Loans 0.00 0.00 Unsecured Loans 59.40 59.40 Long Term Provisions 0.08 0.00 Current Liabilities 50.52 49.43 Trade Payables 47.30 46.44 Other Current Liabilities 3.10 1.55 Short Term Borrowings 0.00 1.28 Short Term Provisions 0.12 0.16 Total Liabilities 212.76 181.81 Net Block 29.97 22.23 Gross Block 38.76 29.75 Accumulated Depreciation 8.79 7.53 Non Current Assets 30.79 25.01 Capital Work in Progress 0.05 1.45 Non Current Investment 0.01 0.00 Long Term Loans & Adv. 0.77 1.34 Other Non Current Assets 0.00 0.00 Current Assets 181.96 156.80 Current Investments 34.02 0.40 Inventories 13.04 15.80 Sundry Debtors 88.57 110.77 Cash & Bank 0.46 20.13 Other Current Assets 45.87 0.88 Short Term Loans & Adv. 44.63 8.81 Net Current Assets 131.44 107.37 Total Assets 212.75 181.81

Description Mar 23
Shareholder's Funds 100.49 Share Capital 32.56 Total Reserves 67.93 Non-Current Liabilities 61.75 Secured Loans 0.00 Unsecured Loans 59.40 Long Term Provisions 0.08 Current Liabilities 50.73 Trade Payables 47.30 Other Current Liabilities 3.31 Short Term Borrowings 0.00 Short Term Provisions 0.12 Total Liabilities 212.97 Net Block 48.12 Gross Block 66.31 Accumulated Depreciation 18.19 Non Current Assets 62.39 Capital Work in Progress 0.68 Non Current Investment 0.00 Long Term Loans & Adv. 13.59 Other Non Current Assets 0.00 Current Assets 150.58 Current Investments 34.02 Inventories 13.04 Sundry Debtors 88.57 Cash & Bank 1.34 Other Current Assets 13.61 Short Term Loans & Adv. 12.37 Net Current Assets 99.85 Total Assets 212.97

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 23 Mar 22
Cash From Operating Activity 22.96 2.25 PBT 38.14 41.70 Adjustment 1.82 3.06 Changes in Working Capital -8.20 -28.05 Cash after chg. in Working capital 31.76 16.72 Interest Paid 0.00 0.00 Tax Paid -8.80 -14.47 Other Direct Exp. Paid 0.00 0.00 Extra & Other Items 0.00 0.00 Cash From Investing Activity -21.18 -12.24 Net Fixed Assets -7.61 Net Investments -33.63 Others 20.06 Cash from Financing Activity -1.53 6.18 Net Cash Inflow / Outflow 0.25 -3.81 Opening Cash & Equivalents 0.13 3.94 Closing Cash & Equivalent 0.38 0.13

Description Mar 23
Cash From Operating Activity 56.05 PBT 38.14 Adjustment 1.56 Changes in Working Capital 25.16 Cash after chg. in Working capital 64.85 Interest Paid 0.00 Tax Paid -8.80 Other Direct Exp. Paid 0.00 Extra & Other Items 0.00 Cash From Investing Activity -55.17 Net Fixed Assets Net Investments Others Cash from Financing Activity -0.93 Net Cash Inflow / Outflow -0.05 Opening Cash & Equivalents 1.31 Closing Cash & Equivalent 1.26

Financial Ratios

Standalone /

Consolidated

Right to Left

Description Mar 23 Mar 22
Book Value (Rs.) 30.86 21.95 ROA 13.63% 15.12% ROE 28.86% 38.48% ROCE 24.01% 31.62% Fixed Asset Turnover 8.61 9.80 Receivable days 96.81 138.69 Inventory Days 14.26 19.79 Payable days 62.43 72.37 Cash Conversion Cycle 48.64 86.11 Total Debt/Equity 0.59 0.85 Interest Cover 151.14 572.29

Description Mar 23
Book Value (Rs.) 30.86 ROA 13.62% ROE 28.86% ROCE 24.01% Fixed Asset Turnover 5.04 Receivable days 96.81 Inventory Days 14.26 Payable days 62.43 Cash Conversion Cycle 48.64 Total Debt/Equity 0.59 Interest Cover 151.14

Top Investors:

jainam broking limited

vikasa india eif i fund - incube global opportunities

niraj rajnikant shah

saint capital fund

Annual Reports:

News Update:

Valiant Laboratories - Quarterly Results
9th Feb 2024, 15:06 PM

Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback